A Study of ASP2138 Given Before Surgery, Then Standard Chemotherapy After Surgery, in People With Pancreatic Ductal Adenocarcinoma

Full Title

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator’s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Kevin Soares’ office at 212-639-3195.